ORIC Pharmaceuticals has promising early data for ORIC-944 and ORIC-114, but remains in very early clinical stages. See why I ...

Both drugs target EZH2, a protein that helps control which genes are active or silent. After just 48 hours of drug exposure, the cells began producing insulin and responding to glucose—just like ...

Top of the list is Ipsen/Epizyme’s selective EZH2 inhibitor Tazverik (tazemetostat ... Last year, the company got NMPA approval for selective EGFR inhibitor sunvozertinib for non-small cell ...